Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 9/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1831026 | 0.86 | — | — | |
| SCHEMBL1781839 | 0.82 | HIF1A (0.50) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL1780932 | 0.82 | — | — | |
| SCHEMBL1782105 | 0.82 | HIF1A (0.50) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| Piperazine SCHEMBL1091869 | 0.82 | HIF1A (0.50) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL1783483 | 0.80 | CXCR4 (0.60) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL577659 | 0.78 | CXCR4 (1.00) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL576838 | 0.78 | CXCR4 (1.00) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL3998680 | 0.78 | CXCR4 (1.00) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| SCHEMBL8503965 | 0.78 | CXCR4 (1.00) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332416-B2 | Process for synthesizing fluorinated cyclic aliphatic compounds | Westfälische Wilhelms-Universität Münster (DE) | 2022-05-17 | — | — | US | disclosed |
| EP-3601203-B1 | PROCESS FOR SYNTHESIZING FLUORINATED CYCLIC ALIPHATIC COMPOUNDS | UNIV MUENSTER WESTFAELISCHE WILHELMS (DE) | 2021-04-07 | — | — | EP | disclosed |
| US-10581001-B2 | Organic electronic component having a charge carrier generation layer and the use of a zinc complex as a P-type dopant in charge carrier generation layers | OSRAM OLED GMBH (DE) | 2020-03-03 | — | — | US | disclosed |
| US-10411197-B2 | Main group metal complexes as P-dopants for organic electronic matrix materials | SIEMENS AKTIENGESELLSCHAFT (DE) | 2019-09-10 | — | — | US | disclosed |
| US-10305047-B2 | Main group metal complexes as p-dopants for organic electronic matrix materials | SIEMENS AKTIENGESELLSCHAFT (DE) | 2019-05-28 | — | — | US | disclosed |
| US-10256422-B2 | Organic electronic component, use of a zinc complex as a p-dopant for organic electronic matrix materials | OSRAM OLED GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| EP-3246960-B1 | MAIN GROUP METAL COMPLEXES AS P-DOPANTS FOR ORGANIC ELECTRONIC MATRIX MATERIALS | SIEMENS AG (DE) | 2018-10-24 | — | — | EP | disclosed |
| EP-2845240-B9 | METAL COMPLEXES AS P-TYPE DOPANTS FOR ORGANIC ELECTRONIC MATRIX MATERIALS | SIEMENS AG (DE) | 2018-10-24 | — | — | EP | disclosed |
| US-20180277778-A1 | ORGANIC ELECTRONIC COMPONENT HAVING A CHARGE CARRIER GENERATION LAYER AND THE USE OF A ZINC COMPLEX AS A P-TYPE DOPANT IN CHARGE CARRIER GENERATION LAYERS | OSRAM OLED GMBH (DE) | 2018-09-27 | — | — | US | disclosed |
| US-9954147-B2 | Optoelectronic device, use of a dual emitter as wavelength conversion material | OSRAM OLED GMBH (DE) | 2018-04-24 | — | — | US | disclosed |
| US-6432900-B1 | ANTISOILANTS | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020049148-A1 | Bleach catalyst and composition and method for bleaching a substrate | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-04-25 | — | — | US | disclosed |
| US-20020023303-A1 | Method for reducing dye fading of fabrics in laundry bleaching compositions | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-02-28 | — | — | US | disclosed |
| US-20020013246-A1 | Composition and method for bleaching laundry fabrics | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-01-31 | — | — | US | disclosed |
| US-20020010120-A1 | Composition and method for bleaching a substrate | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-01-24 | — | — | US | disclosed |
| US-20020010121-A1 | Bleaching and dye transfer inhibiting composition and method for laundry fabrics | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-01-24 | — | — | US | disclosed |
| US-6340661-B1 | FOR BLEACHING FABRIC STAINS WITHOUT UNACCEPTABLE TRANSFER OF DYES BETWEEN FABRICS | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2002-01-22 | — | — | US | disclosed |
| US-20010025019-A1 | Bleaching composition | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2001-09-27 | — | — | US | disclosed |
| US-20010009271-A1 | Bleaching composition | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2001-07-26 | — | — | US | disclosed |
| WO-2001048138-A2 | BLEACHING COMPOSITION | UNILEVER N.V. (NL) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332416-B2 | Process for synthesizing fluorinated cyclic aliphatic compounds | HRH4, HRH1, AHR | CXCR4 1059/4885SMN1; SMN2 4460/4885ALDH1A1 2748/4885 |
| US-10581001-B2 | Organic electronic component having a charge carrier generation layer and the use of a zinc complex as a P-type dopant in charge carrier generation layers | SCO2, NCOA4, NR4A2 | CXCR4 394/4885SMN1; SMN2 2217/4885ALDH1A1 2367/4885 |
| US-10305047-B2 | Main group metal complexes as p-dopants for organic electronic matrix materials | SCO2, SOD3, NCOA3 | CXCR4 3361/4885SMN1; SMN2 1186/4885ALDH1A1 1949/4885 |
| US-20180277778-A1 | ORGANIC ELECTRONIC COMPONENT HAVING A CHARGE CARRIER GENERATION LAYER AND THE USE OF A ZINC COMPLEX AS A P-TYPE DOPANT IN CHARGE CARRIER GENERATION LAYERS | SCO2, NCOA4, NR4A2 | CXCR4 394/4885SMN1; SMN2 2217/4885ALDH1A1 2367/4885 |
| US-10411197-B2 | Main group metal complexes as P-dopants for organic electronic matrix materials | SCO2, KMO, NOXO1 | CXCR4 1914/4885SMN1; SMN2 1418/4885ALDH1A1 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.